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Introduction: Human adipose-derived stromal cells (hASCs), due to their relative feasibility of isolation and ability to
secrete large amounts of angiogenic factors, are being evaluated for regenerative medicine. However, their limited
culture life span may represent an obstacle for both preclinical investigation and therapeutic use. To overcome this
problem, hASCs immortalization was performed in order to obtain cells with in vitro prolonged life span but still
maintain their mesenchymal marker expression and ability to secrete angiogenic factors.
Methods: hASCs were transduced with the human telomerase reverse transcriptase (hTERT) gene alone or in
combination with either SV-40 or HPV E6/E7 genes. Mesenchymal marker expression on immortalized hASCs lines
was confirmed by flow cytometry (FC), differentiation potential was evaluated by immunocytochemistry and ELISA
kits were used for evaluation of angiogenic factors. Green fluorescent protein (GFP) gene transduction was used to
obtain fluorescent cells.
Results: We found that hTERT alone failed to immortalize hASCs (hASCs-T), while hTERT/SV40 (hASCs-TS) or hTERT/
HPV E6/E7 (hASCs-TE) co-transductions successfully immortalized cells. Both hASCs-TS and hASCs-TE were cultured
for up to one year with a population doubling level (PDL) up to 100. Comparative studies between parental not
transduced (hASCs-M) and immortalized cell lines showed that both hASCs-TS and hASCs-TE maintained a
mesenchymal phenotypic profile, whereas differentiation properties were reduced particularly in hASCs-TS.
Interestingly, hASCs-TS and hASCs-TE showed a capability to secrete significant amount of HGF and VEGF.
Furthermore, hASCs-TS and hASCs-TE did not show tumorigenic properties in vitro although some chromosomal
aberrations were detected. Finally, hASCs-TS and hASCs-TE lines were stably fluorescent upon transduction with the
GFP gene.
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Conclusions: Here we demonstrated, for the first time, that hASCs, upon immortalization, maintain a strong
capacity to secrete potent angiogenic molecules. By combining hASCs immortalization and their paracrine
characteristics, we have developed a “hybridoma-like model” of hASCs that could have potential applications for
discovering and producing molecules to use in regenerative medicine (process scale-up).
In addition, due to the versatility of these fluorescent-immortalized cells, they could be employed in in vivo
cell-tracking experiments, expanding their potential use in laboratory practice.Introduction
Human adipose stromal cells (hASCs) have various prac-
tical advantages compared to mesenchymal stromal cells
(MSCs) isolated from other tissue sources, such as their
ease of being obtained, greater stem cell yields than from
other stem cell reservoirs and, most importantly, min-
imal invasive procedures. These practical aspects make
hASCs a real and powerful therapeutic tool for the treat-
ment of numerous human diseases [1,2]. However, to date,
translation of MSCs’ preclinical results to the bedside still
have serious problems to be solved. One of them certainly
relates to the high variability of MSC preparations among
different laboratories. The reasons for the variability are
multiple and can include the tissue origin of the MSCs
(fat, bone marrow, umbilical cord blood and so on), the
gender and age of the donors, as well as the methods of
isolation and the culture conditions used [3-5]. Besides
this, the use of MSCs in clinical care is also limited by
technical problems regarding their particularly limited
life-span for ex-vivo expansion [6]. In general, MSCs can
easily adapt to culture conditions and, particularly in the
early stages of culture, they show a good proliferative rate.
But, during their expansion, whatever their tissue origin,
and the age or gender of the donor, MSCs undergo senes-
cence and significantly decrease cell growth sometime
after a very limited number of in vitro cell passages [7,8].
This growth limit definitely represents a serious problem
related to both MSCs and hASCs, because usually a
significant number of cells and multiple cell treatments
might be required for treating human diseases.
A possible solution to circumvent MSCs’ preparation
heterogeneity and their limited growth expansion is
immortalization by genetic manipulation. Generally, this
strategy requires abrogation of p53 and pRB-mediated
terminal proliferation and/or activation of a telomerase
reverse transcriptase (hTERT) maintenance mechanism
[9]. Several methods have been developed for immortaliz-
ing cells in vitro [10]. Among these, the introduction of
viral genes, such as SV40 [11] or human papilloma-virus
(HPV) E6/E7 genes [12] and the hTERT gene [13-15] have
been widely used. On this basis, the aim of the present
work was to immortalize different hASC preparations in
order: 1) to produce new human stromal cell lines withmore stable characteristics to be used both in vitro and
in vivo in preclinical investigations, and 2) to use these
cell lines as a source for the isolation and production of
angiogenic factors.
Here we show that by combining hTERT with either
SV40 or E6/E7, we were able to produce eight different
hASC cell lines. All cell lines were characterized by flow
cytometry and expanded in vitro up to 100 population
doubling levels (PDL). The cells maintained their typical
mesenchymal marker expression and an elevated cap-
ability to secrete angiogenic factors, such as hepatocyte
growth factor (HGF) and vascular endothelial growth
factor (VEGF), in the culture medium. We conclude that
hASCs are ideal to produce immortalized hMSC cell lines
that are able to maintain their phenotype and their func-
tional characteristics. These cells could be exploited for
the identification and extraction of hASCs-derived an-
giogenic molecules that could be used in regenerative
medicine. Finally, by coupling hASCs immortalization
and their paracrine characteristics, we have developed a
“hybridoma-like model” that may have a potential appli-
cation in discovering and producing molecules to use in
regenerative medicine (process scale-up).
Methods
Isolation of hASCs
After approval by the Ethical Committee of “F. Miulli”
Hospital (Acquaviva, Bari, Italy), human fat specimens
were obtained from four patients undergoing abdominal
surgery. Informed consent was obtained from all pa-
tients in this study. Isolation of cells was performed as
previously described [16] and four different hASCs cell
populations were generated and subsequently used to be
immortalized. All hASCs cells were cultured in a EGM
Bullet kit (Lonza, Verviers, Belgium) supplemented with
10% FCS, antibiotics and L-Glutamine 2 mM, at 37°C, 5%
CO2. In vitro cell growth was monitored by cell number
count and cumulative PDL calculation. Population doubling
(PD) gained at each passage was determined using the
following formula: PD[n/(n-1)] = (Log(Nn / Nn-1))/Log 2,
where n: passage, n-1: previous passage, Nn: cell number at
passage n and Nn-1: cells plated at passage n-1. Cumulative
PDL is the sum of PDs [17].
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Viral transduction of hASCs is a well-established method
to transduce genes into cells and obtain their expression
[18]. To induce hASCs immortalization, hTERT alone, or
in combination with SV40 and E6/E7 genes, was used.
The Lentiviral vectors pLenti-hTERT, pLenti-III-SV40 and
pLenti-III-HPV-16 E6/E7 were purchased from Applied
Biological Materials Inc. (Richmond, BC, Canada). Cells
were transduced according to the manufacturer’s protocol.
Briefly, 5.0 × 103 cells/cm2 were plated in six-well tissue
culture plates and incubated at 37°C, 5% CO2 until they
reached 65 to 70% confluence. Afterwards, medium was
replenished with pLenti-hTERT viral suspension and fresh
medium (ratio 1:1) in the presence of 8 μg/ml polybrene.
Cells were then incubated overnight at 37°C, 5% CO2.
After 24 hours, the medium was changed and cells were
left in culture for three days and then detached with tryp-
sin. An identical scheme was followed for pLenti-III-SV40
and pLenti-III-HPV-16 E6/E7 lentiviral transduction. For
each hASC-T population, an aliquot of cells was trans-
duced with either the SV40 or E6/E7 gene. All cells were
grown in the above-mentioned medium and the following
nomenclature was assigned: M, non-transduced (Mother,
putative cell preparations); T, hTERT-transduced; TS, hTERT/
SV40-transduced; TE, hTERT/E6/E7-transduced.Doubling time assay
To estimate the time required by cells to duplicate their
number, doubling time assays were performed. A total of
13.0 × 103 cells/cm2 were plated in 12-well tissue culture
plates (in triplicate) with 1 ml/well of culture medium and
incubated at 37°C, 5% CO2, for 24, 48, 72 and 96 hours.
At each time point, cells were washed once with 2 ml/well
PBS 1X, detached with 0.5 ml/well trypsin/EDTA, resus-
pended in 1.5 ml/sample in complete culture medium and
counted in a hemacytometer. We obtained three different
cell count values for all samples tested (M, T, TS and TE,
respectively).Cell morphology and senescence-associated
β-galactosidase assay
Cell morphology of hASCs-M, hASCs-T, hASCs-TS and
hASCs-TE was observed and analyzed using a phase
contrast microscope (CKX41, Olympus, Tokyo, Japan).
Cells were than photographed at 10X magnification with
a C-7070 digital compact Camera (Olympus,).
Senescence-associated β-galactosidase activity was
evaluated with a senescence cell histochemical staining
kit (SIGMA Aldrich, USA), according to protocol in-
structions. Briefly, 3.0 × 103 cells/cm2 were plated in
12-well tissue culture plates (in triplicate) and incubated
at 37°C, 5% CO2 for 48 hours. Cells were then washed
twice with 1 ml/well PBS 1X and fixed for seven minutesat room temperature. After three washes, cells were
stained at 37°C overnight and visualized under a microscope.
Immunophenotypic characterization
Cultures of hASCs-M, hASCs-T, hASCs-TS and hASCs-
TE were phenotypically characterized by flow cytometry
(FC). After trypsinization, cells were resuspended with FC
buffer (pH 7.2 PBS, BSA 0.5%, sodium azide 0.02%) at a
concentration of 0.1 x 106/100 μl. Cells were incubated
with fluorescently labeled antibodies for 30 minutes at
room temperature in a dark room and then washed
with FC buffer to remove non-conjugated antibodies.
Fluorescein isothiocyanate (FITC-F) or phycoerythrin
(PE) conjugate-antibodies were used: CD90PE, CD105PE,
CD34PE, CD45F, CD44F, CD106PE, CD146PE (Immuno-
tech®, Milan, Italy), HLA-IF, HLA-IIPE (Biolegend®, Italy),
CD73PE, SSEA-4PE (R&D®, Milan, Italy). Epics "XL-MCL"
(Beckman Coulter, USA) flow cytometer was used for
analyzing fluorescent immunophenotypic marker signals.
At least 10,000 events for test samples were acquired.
Sample histogram elaboration was performed with EXPO
32 software to assess fluorescent distribution.
Osteogenic and adipogenic differentiation
hASCs differentiation capability was assessed by investigat-
ing osteogenic and adipogenic induction. For osteogenic
differentiation, cells were seeded into six-well culture plates
and at a density of 5.0 × 103 cells/cm2 and cultivated in
NH OsteoDiff medium (Miltenyi Biotec, GmBH) for
two weeks. Osteogenic potential was assessed by alka-
line phosphatase activity with SIGMA FAST BCIP/NBT
substrate (SIGMA-Aldrich, USA).
For adipogenic differentiation, cells were placed into
six-well culture plates at a density of 5.0 × 103 cells/cm2
and cultivated in NH AdipoDiff medium (Miltenyi Biotec,
GmBH) for three weeks. Adipogenic potential was
assessed by Oil Red O (SIGMA-Aldrich, USA) staining.
HGF AND VEGF secretion
To evaluate HGF and VEGF secreted by hASCs-M,
hASCs-T, hASCs-TS and hASCs-TE cultured cells, cell
supernatants were collected and analyzed as follows. A
total of 20.0 × 104 cells/cm2 were plated in T-25 flasks
with 4 ml complete medium at 37°C, 5% CO2 for
72 hours. At the end of incubation, cell supernatants
were harvested and centrifuged at 2,500 rpm for 10
minutes at 4°C to remove cell debris, and cryopreserved
at −80°C until use. Growth factor production was tested
by enzyme immunoassay ELISA kits (Human VEGF and
HGF Quantikine ELISA Kit, R&D Systems, Minneapolis,
MN, USA). Protein concentration was measured following
the standard guidelines illustrated in the ELISA kit
used. The culture medium alone (containing FBS) was
used as a negative control. Absorbance was measured
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Italy). Cytokine concentration in conditioned media was
obtained after subtracting the value obtained by the nega-
tive control (background value). For each sample analyzed,
HGF and VEGF secretion were normalized by the total
number of cells and expressed as pg/105 cells.
Karyotyping
Mid-log cell cultures were arrested with 100 ng/ml colce-
mid, disrupted in 0.075 M KCl solution at 37°C, fixed with
a 3:1 mixture of methanol and acetic acid, and allowed to
air dry. Following brief trypsinization, chromosomes were
stained with quinacrine dihydrocloride (SIGMA, St. Louis,
MO, USA). For all cell lines analyzed (hASC-M, hASC-T,
hASC-TS and hASC-TE) karyotyping was carried out at
the following passages: 10, 16, 19 and 26. Karyogram ana-
lyses were performed using Leica CW4000 Karyo V1.1
software (Leica Imaging Systems, Cambridge, UK).
Cellular transformation
To detect in vitro cellular transformation, a soft-agar assay
was performed. Briefly, 12-well tissue culture plates were
coated with 1:1 mixture of complete medium and 1% base
agar (SIGMA-Aldrich, USA) and, after solidification, cells
were seeded in triplicate at a density of 2.5 × 103 cells/cm2.
Cells were plated in a 1:1 mixture of complete medium
and 0.7% agarose (Lonza, Rockland, ME USA), fed three
times a week and incubated at 37°C, 5% CO2 for 28 days.
Cell colonies were fixed with 1% formaldehyde, stained
with 0.05% Crystal Violet, and counted. PC-3 cells (prostate
tumor) were used as a positive control.
Green fluorescent protein (GFP)-transduction
To obtain hASCs-TS and hASCsTE-fluorescent cells,
two different approaches were used. Using the first
method, as described by Dull et al. [19], HEK 293 T cells
were transfected with pCCLsin.PPT.hPGK.GFPpre, pMDL,
pRSV-REV and pVSV-G plasmids in the presence of
Lipofectamine (Invitrogen, Carlsbad, CA, USA). After
48 hours, HEK 293 T cell conditioned medium was
filtered and used to transduce hASCs cells. To increase
transduction efficiency, polybrene 8 μg/ml was added.
hASCs underwent three consecutive infection cycles.
With the second method, lentiviral particles purchased
from Lentigen (Baltimore, MD, USA) were used to trans-
duce hASCs according to the manufacturer’s protocol.
Both methods generated hASCS that stably expressed
GFP and fluorescence did not diminish during the whole
period of culture.
Statistical analysis
Statistical differences were evaluated using Student’s
t-test where applicable. P-values smaller than 0.05 were
accepted as significant.Results
Proliferation of hASCs before and after transfection with
hTERT alone or combined with either SV40 or E6/E7
Human fat specimens were obtained from four pa-
tients (two males and two females aged between 21
and 59 years) and derived hASC primary cultures named
hASC 20, hASC 36, hASC 72 and hASC 79 underwent
immortalization procedures. The proliferative rates of all
different cultures were followed over time by evaluating
the PDL. In Figure 1, the PDL values of the non-
transduced original hASCs (−M), hTERT transduced
(hASCs-T), hTERT + SV40 transduced (hASCs-TS) and
hTERT + E6/E7 transduced cells (hASCs-TE) are shown.
All non-transduced hASCs (hASC 20-M, hASC 36-M,
hASC 72-M and hASC 79-M) showed very low PDL
values; they grew slowly in the first 50 days of culture,
afterwards they stopped proliferation. All the different
hASC-Ms were able to remain in culture for a long time
but did not increase their cell number. Transduction of
cells with hTERT alone slightly increased the PDL values
(≤20), with the only exception being hASC-20 T. How-
ever, like the non-transfected counterpart, after 50 to
80 days of culture, the cells ceased to proliferate. In
contrast, all the hASCs transfected either with the com-
bination hTERT + SV40 (hASCs-TS) or with hTERT +
E6/E7 (hASCs-TE) acquired a significant proliferative
capability, reaching very high PDL values and still grow-
ing after 180 (hASC 20-TS/TE and hASC 36-TS/TE)
and 300 (hASC 72-TS/TE and hASC 79-TS/TE) days of
culture. Comparing the PDL values of hASCs-TS versus
hASCs-TE, we observed that three out of four hASCs-TS
(hASC 20-TS, hASC 36-TS and hASC 79-TS) showed a
better proliferative activity, suggesting that the hTERT +
SV40 co-transduction of hASCs was more efficient than
hTERT + E6/E7 in improving growth rate. A summary of
the PDL values obtained after 180 and 300 days of hASC-
TS and hASC-TE culture is reported in Table 1.
To better characterize the effect of different types of
transductions on the proliferation of hASCs cultures, we
also evaluated the cells doubling time (DT) before and
after transfections. As shown in Figure 2, hASC-TS and
hASC-TE cells required less time to duplicate when com-
pared to their non-transduced counterpart and hTERT-
transduced cells. As reported in Tables 2, the DT mean
value was 32.1 ± 8.5 hours for the hASCs-TS at cell pas-
sage 21, 39.1 ± 4.2 hours for the hASCs-TE at cell passage
21, 73.8 ± 12.7 hours for the hASCs-T at cell passage 17
and 53.2 ± 9.3 hours for the hASCs-M at cell passage 7.
Notably, although hASCs-TS and hASCs-TE were tested
at higher cell passages than hASCs-T, the DT mean values
of the hASCs-TS and hASCs-TE were much lower than
hASCs-T and hASCs-M, thus confirming that subsequent
transduction of hASCs-T with SV40 or E6/E7 produced
cell lines with very high PDL values.
Figure 1 Growth rate graphics of not transduced (M), hTERT-transduced (T), hTERT/SV40- (TS) and hTERT/E6E7- (TE) co-transduced
cells. Four different hASCs cell lines were tested for cell immortalization, and eight immortalized cell lines were generated (TS or TE). Population
Doubling Levels (PDL) were calculated for each cell line over time. PDL represents the sum of PD values obtained when cells were detached and
re-plated (see Material and methods for details).
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display an increase in cell size and β-galactosidase (β-Gal)
activity as senescence markers
The change in cell morphology, as well as the expression
of β-gal, a marker of senescence, was monitored in order
to further characterize the parental and transduced cell
lines. Senescent cells usually display an increase of cell size
and β-galactosidase activity, that is absent in quiescent,Table 1 Days in culture and PDL values of immortalized
cells
Cell line Number of passages
before cryo-storing
Days in culture PDL VALUE
hASC-20 TS 45 180 89.48
hASC-20 TE 45 180 64.61
hASC-36 TS 40 180 106.05
hASC-36 TE 40 180 93.40
hASC-72 TS 65 300 104.39
hASC-72 TE 65 300 121.45
hASC-79 TS 65 300 162.48
hASC-79 TE 65 300 156.65
Numerical data of immortalized hASCs. Culture passages prior to cryo-preservation,
days in culture and population doubling level (PDL).
Figure 2 Doubling time assay of hASC-M, hASC-T, hASC-TS and
hASC-TE cells. A total of 13.0 x 106 cells/cm2 were plated at T0 and
detached at the indicated time points. Three different values were
obtained for each cell line. Cells were evaluated at the following cell
culture passages: hASCs-M P7; hASCs-T P17; hASCs-TS and hASCs-TE
P21. The histogram represents the mean value ± SD of four different
experiments.
Table 2 Mean doubling time of hASCs cells
Cell line Mean doubling time (hrs) P-value vs M P-value vs T
hASC-M 53.2 ± 9.3
hASC-T 73.8 ± 12.7 0.04
hASC-TS 32.1 ± 8.5 0.02 0.0004
hASC-TE 39.1 ± 4.2 0.03 0.0006
Mean doubling time values of non-transduced and T-, TS- or TE-transduced
cells. Statistical significance vs non-transduced (M) or T-transduced cells.
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of different cell lines were analyzed by light microscopy
during cell expansion. At an early phase of 32 days of
culture, both non- and transduced hASCs showed a simi-
lar “fibroblast-like” shape and usually formed an almost
uniform cell monolayer at confluence (Figure 3A). After
147 days of culture, hASCs-M and the hASCs-T signifi-
cantly changed their initial morphology, increasing in cellA
hASC-M
hASC-T
hASC-TS
hASC-TE
Figure 3 Cell morphology of hASC-M, −T, −TS and -TE cells. A: Cells at in
Magnification 4X.size and reducing the capability to reach a confluent
monolayer, whereas hASCs-TS and hASCs-TE maintained
the initial morphology, continuing to generate a very
dense cell monolayer even with cell overgrowth in some
areas (Figure 3B). Thus, the morphological appearance
seems to indicate that only the cells of hASCs-M and
hASCs-T underwent a senescence process. To confirm
and quantify the senescent cell process, β-gal staining was
performed on hASC-M, hASC-T, hASC-TS and hASC-TE
cultures. Cells cultured for five months were seeded at low
density in order to better detect the positive staining to β-
gal. As shown in Figure 4, hASCs-M and hASCs-T showed
a significant positivity to β-gal. The calculated percentages
of senescent cells were, respectively, 77.21 ± 8.88 and
74.51 ± 6.41. To the contrary, very few positive hASCs-TS
and hASCs-TE were detected and the percentages of sen-
escent cells were 2.14 ± 1.11 and 7.15 ± 6.33, respectively
(P <0.01 vs hASCs-M).B
itial culture period (32 days); B: Cells at late culture period (147 days).
Figure 4 β-galactosidase (β-gal) senescence evaluation of hASC-M, −T, −TS and -TE cells. Representative β-gal staining of cells. The
percentage of senescent cells were calculated by analyzing eight different fields for each cell line. The histogram represents the mean value ± SD
of four different experiments **P <0.01 vs hASCs-M. Magnification 10X.
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mesenchymal markers, acquire stem cell markers and
increase mobilization associated markers
During culture, hASCs phenotypic characterization was
conducted to establish whether transduction with hTERT
and co-transduction with either hTERT+ SV40 or hTERT +
E6/E7 could modify the expression of the original mesen-
chymal marker profiles as well as markers involved in cell
homing and stemness. For this reason, the expression of
CD90, CD73, CD105, CD34, CD45, HLA-I and HLA-II,
which have been described as MSC immunophenotypes
was evaluated on all cell lines with fluorescence-activated
cell sorting (FACS) analysis [21]. We found that the ori-
ginal hASC-M cultures and all transduced cell populations
were positive for CD90, CD73, CD105 and HLA-I, and
negative for CD34, CD45 and HLA-II, thus confirming
the MSC immunophenotype (Table 3). Of note, CD105
showed a decrease in hASCs-TS and hASCs-TE cellsurface expression (48.1% and 37.0%, respectively)
compared to hASCs-M and hASCs-T, but all cell pop-
ulations displayed a similar membrane distribution
(Figure 5).
We further investigated the expression of CD44
(H-CAM) and CD106 (VCAM-1) as homing markers
[22] and CD146 (MUC18), and SSEA-4 (Stage-Specific
Embryonic Antigen-4) as stemness markers [23,24]. All
hASC cultures showed 100.0% positivity for the homing
cell marker CD44, before and after transduction. To the
contrary, the percentage CD106 positive cells signifi-
cantly increased up to 46.8% in hASC-TE (Table 3) and
showed a more homogeneous antigen membrane
distribution compared to the other cell populations
(Figure 5).
Interestingly, the CD146 surface expression was in-
creased in hASC-TS and hASC-TE cells (26.0% and
60.0%, respectively) compared to hASC-M and hASC-T
Table 3 Relative expression percentages of surface
markers analyzed by flow cytometry
hASC-M hASC-T hASC-TS hASC-TE
CD90 81.0 ± 3.4 70.0 ± 17.0 96.3 ± 1.6 77.0 ± 21.0
CD73 94.0 ± 2.4 96.0 ± 2.1 85.0 ± 2.3 92.5 ± 3.6
CD105 83.0 ± 5.1 81.0 ± 0.3 48.1 ± 2.0 37.0 ± 16.0
CD34 1.5 ± 0.1 1.2 ± 0.5 0.6 ± 0.1 0.9 ± 0.3
CD45 0.8 ± 0.3 1.2 ± 0.1 1.0 ± 0.2 0.5 ± 0.1
HLA-I 96.3 ± 2.1 80.0 ± 8.0 98.0 ± 0.4 92.0 ± 6.0
HLA-II 0.6 ± 0.2 0.8 ± 0.4 1.6 ± 0.6 0.9 ± 0.3
CD44 97.0 ± 0.4 94.0 ± 3.0 98.7 ± 0.2 99.5 ± 0.3
CD106 12.0 ± 6.0 30.5 ± 12.0 12.0 ± 0.2 46.8 ± 19.8
CD146 4.8 ± 1.0 4.1 ± 0.4 26.0 ± 6.0 60.0 ± 14.0
SSEA-4 23.0 ± 2.8 29.0 ± 3.0 16.0 ± 6.0 30.0 ± 12.0
Phenotypic panel of markers analyzed by flow cytometry on hASC-M, hASC-T,
hASC-TS and hASC-TE cells. Relative expression percentages of each antigen
are reported. Values are the mean ± S.E. of five independent experiments.
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expressed in all cell populations.Immortalized hASC-TS but not hASC-TE significantly
reduced their differentiation potential
We further investigated the capability of immortalized
hASC-TS and hASC-TE cell lines to retain differentiation
potential. hASC-M (P8), hASC-T (P8), hASC-TS (P25)
and hASC-TE (P25) cells were cultured under osteogenic
and adipogenic differentiation conditions. As shown in
Figure 6A, hASC-M cells were able to differentiate into
the osteogenic lineage after 14 days of induction. Similarly,
hASCs-T, although less intense than control, showed a
positive staining. Finally, we found that hASC-TS cells lost
their differentiation potential, while all the hASC-TE cell
lines retained a significant capability to differentiate into
the osteogenic cell lineage.
Adipogenic induction evidenced that hASC-M and,
to a lesser extent, hASC-T and hASC-TS cells stained
for Oil Red O after 21 days. Conversely, hASCs-TE
adipogenic potential was similar to non-transduced
cells (Figure 6B).Immortalization of hASCs did not substantially reduce
their angiogenic potential
It is widely demonstrated that hASCs are able to induce
angiogenesis through the production and secretion of an-
giogenic factors and cytokines [25-27], such as HGF and
VEGF [28,29]. So, we investigated whether the immortal-
ized hASCs-TS and hASCs-TE continue to produce these
growth factors in vitro. For this aim, conditioned media
(CM) from hASCs-M and hASCs-T (passages 5-13-21),
hASCs-TS and hASCs-TE (passages 16-22-38) were col-
lected and, subsequently, HGF and VEGF concentrationwas measured. The values were normalized by the total
number of cells and expressed as pg/105 cells.
As shown in Figure 7A, hASCs-M produced about
3,500 pg/105 cells of HGF in CM after 72 hours of culture,
thus confirming that this growth factor is highly produced
by primary cultures of hASCs. The level of HGF secreted
by hASC-T cells were slightly reduced compared to the
parental hASCs-M. On the other hand, hASC-TS cell lines
showed a statistically significant (P <0.05) reduction of
HGF secretion compared to the parental hASCs-M, but a
significant increased level was secreted by hASC-TE cell
lines (P <0.05).
The amount of VEGF secreted by hASCs-M cell lines
in CM (Figure 7B) was about 2,500 pg/105 cells. As ob-
served for HGF production, hASC-T cell lines showed
reduced levels of VEGF in CMs. Likewise, a statistically
significant (P <0.05) reduction of VEGF was observed in
all hASCs-TS CMs compared to the parental hASCs-M.
To the contrary, a significant amount of VEGF was de-
tected in hASCs-TE CM similar to the levels secreted
by the parental hASCs-M.
Immortalized hASC-TS and hASC-TE showed significant
changes in karyotype and in vitro transformation
To assess whether transduction of hASCs cells either
with hTERT alone or in combination with SV40 and
HPV E6/E7 could induce chromosomal modifications,
cytogenetic studies were conducted. Representative ex-
amples of hASC-M, hASC-T, hASC-TS and hASC-TE
karyotype analysis at culture passage 26 are reported in
Figure 8A. None of the hASC-M cell lines analyzed
showed chromosomal alterations, whereas chromosomal
aberrations and unbalanced translocations were evidenced
in hASC-T, hASC-TS and hASC-TE cells. In particular,
hASC immortalization with hTERT and SV40 determined
a significant alteration of the normal cell karyotype,
producing cells with three additional chromosomes. To
further understand how this altered karyotype could
affect cell behavior and, more specifically, neoplastic
transformation, a soft agar assay was performed. As
shown in Figure 8B, although elevated cell number and
prolonged culture time (21 or 28 days) were used as
experimental conditions, only positive control (PC-3,
prostate tumor) formed colonies. All cell lines behaved
like the negative control (medium only).
hASC-TS and hASC-TE cells can be successfully transduced
with GFP for further in vivo tracking and homing studies
Due to the importance of producing labeled hMSC
lines for investigating their homing and tracking in vivo
[30], we also investigated the possibility of stably label-
ing hASCs-TS and hASCs-TE with GFP. For this aim,
hASC-TS and hASC-TE cell lines were transduced with
lentiviral particles containing the GFP gene. As shown
Figure 5 Flow cytometry histograms of CD105, CD106, CD146 and SSEA-4 surface antigens. The Mean Fluorescence Intensity (MFI) of
hASC-M, hASC-T, hASC-TS and hASC-TE cell populations was reported on the x-axis. Black line curves represent isotypic control; gray curves
represent fluorescence peaks.
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lines expressed GFP protein, albeit with different trans-
duction efficiency. In fact, hASC-TS cells appeared brighter
than the hASCs-TE. Furthermore, GFP-fluorescent-labeled
cells were able to proliferate continuously, maintaining
their GFP expression and increasing their cell number
(data not shown).
Discussion
Human adipose tissue may represent an interesting reser-
voir of cells for therapeutic approaches. However, since
the hASC population is not characterized by prolonged
lifespan and stable characteristics, these aspects still
pose significant limitations to their clinical use [31-33].Different immunophenotypic and functional criteria have
been proposed to better characterize hASCs [34], never-
theless the problem remains partially unsolved.
The cell immortalization process could be performed
on primary hASC culture preparations in order to
bypass the problems related to limited lifespan and cell
heterogeneity [35,36]. It is well known that hASCs re-
lease significant amounts of cytokines and growth factors
[37], and cell immortalization may be useful in facilitating
the production/purification of secreted factors by bypassing
limits imposed by the occurrence of senescence (scale-up
process).
Considering these reasons, in the present work we im-
mortalized four different hASCs primary cultures. All the
Figure 6 Differentiation potential of hASC-M, hASC-T, hASC-TS and hASC-TE cells. hASC-M (P8), hASC-T (P8), hASC-TS (P25) and hASC-TE (P25)
cells were cultured under osteogenic and adipogenic differentiation conditions. A: Osteogenic induction was evaluated by alkaline phosphatase activity
after 14 days of culture. B: Assessment of adipogenic differentiation by Oil Red O staining after 21 days of culture is shown. Magnification 10X.
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characterized and compared to native non-transduced
hASCs. Immortalized cells’ capability to release the
angiogenic factors HGF and VEGF was also evaluated
together with their ability to express GFP in a stable
manner in order to potentially use these cells for in vivo
cell-tracking.
Two different cell immortalization approaches were used.
We started using the hTERT gene to avoid use of viral
proto-oncogenes. Moreover, the successful immortalization
of adipose tissue stromal cells has been previously de-
scribed [38-40]. In our studies we did not achieve the
expected results, despite the use of different MOI
(Multiplicity of Infections) values and antibiotic-selection.
Further attempts were done by treating hTERT-transduced
cells with Y-27632 (data not shown), a Rho kinase inhibitor
which has been demonstrated to efficiently immortalize
human keratinocytes [41], but this experimental procedure
also failed. Additionally, hASC-T cells showed elevated
telomerase activity compared to non-transduced cells,
but were unable to proliferate and expand in vitro (data
not shown).
Thus, we decided to combine hTERT with SV40 or HPV
E6/E7 genes, either by ex-novo transduced cells or with
previously hTERT-transduced cells. In all cases we ob-
tained cells with a prolonged in vitro proliferation rate and
elevated cell expansion capabilities. PDL values showed
high growth rates of both hASC-TS and hASC-TE cell
lines. To the contrary, hASCs-M and hASCs-T weretotally unable to grow after 50 to 80 days of culture.
Higher PDL values were obtained by hASCs-TS compared
to hASCs-TE. This could be linked in part to a lower
doubling time required by hASCs-TS, although other
mechanisms may determine this difference. For example,
it is well established that viral SV40 and HPV E6/E7 genes
differently affect cell-cycle check-points [42]. Additional
important differences between immortalized hASCs-TS
and hASCs-TE, and control hASCs-M and hASCs-T were
detected. Indeed, it was observed that hASCs-TS and
hASCs-TE retained a “fibroblast-like” cell morphology
and did not express the β-galactosidase senescence
marker over time. Conversely, the control hASCs-M
and hASCs-T enlarged their size in culture and showed
β-galactosidase activity. At least in part, these data con-
cord with what was observed for proliferation; in fact,
senescent cells lose their ability to divide although they
tend to remain viable for a long time.
Immunophenotypic analysis revealed that immortali-
zation did not affect cell surface marker expression sub-
stantially compared to non-transduced cells and most
importantly, the expression remained unaltered over
time. The only exceptions were the increase of CD106
in hASC-TE and CD146 in hASC-TS and hASC-TE
cells when compared to non-transduced cells. The rea-
son and significance of these variations still need to be
clarified.
Our study showed that hASC-TS and hASC-TE cells
differed in terms of differentiation capabilities. hASC-TS
Figure 7 Angiogenic potential of immortalized hASCs.
Conditioned media from hASCs-M and hASCs-T (passages 5-13-21),
hASCs-TS and hASCs-TE (passages 16-22-38) were collected and
subsequently analyzed by ELISA assay to evaluate the concentration
of HGF and VEGF. For each sample analyzed, HGF and VEGF secretion
were normalized by the total number of cells and expressed as pg/105
cells. A) The HGF secretion was significantly decreased in hASC-TS cell
lines and increased in hASC-TE cell lines. B) The VEGF secretion was
similar in hASC-M and hASC-TE cell lines but significantly decreased in
hASC-TS cell lines. Each histogram represents the mean ± SD of four
different experiments. *P <0.05 vs hASC-M protein levels.
Balducci et al. Stem Cell Research & Therapy 2014, 5:63 Page 11 of 15
http://stemcellres.com/content/5/3/63lines were able to differentiate only into adipogenic-like
cells, while hASC-TE retained the capacity to differentiate
into adipogenic and osteogenic cell lineages. Our results
confirm previous data on the differentiation potential of
immortalized cells. In fact, it has been demonstrated that
co-expression of hTERT and HPV-E7 in human pre-
adipocytes did not alter their ability to differentiate [15].
In addition, Tátrai et al. [43] recently reported that hASCs
immortalized by co-transducing cells with hTERT and SV40
were unable to differentiate into an osteogenic lineage.
The same authors evidenced that hASCSV40+hTERT cells
showed an aggressive in vitro behavior but were unable to
form tumors in NOD/SCID gamma mice. Here, by using
a soft agar in vitro transformation assay, we demonstrated
that hASCs-TS and hASCs-TE were unable to give rise to
colonies, albeit all immortalized lines showed significant
chromosomal alterations. It remains to be investigated
whether hASCs-TS and hASCs-TE are able to form
tumors in vivo.Several findings have demonstrated that hASCs are able
to induce angiogenesis through a paracrine mechanism
that, at least in part, could involve the secretion of HGF
and VEFG [44,45]. Interestingly, it has recently been
reported that rejuvenation or immortalization of adipose
stromal cells may maximize their paracrine properties and
improve their therapeutic potential. Madonna et al. [46]
showed that overexpression of hTERT and myocardin
genes in ASCs induced cell rejuvenation, increased their
VEGF production and promoted revascularization and tis-
sue repair when transplanted in a murine model of hind-
limb ischemia. Recent studies have elucidated a possible
role of CM with regenerative activities [47,48]. Song at al.
[49] reported that transduction of MYC-immortalized
hASCs with the constitutive active (CA)-AKT gene in-
creased their VEGF secretion. Furthermore, injection of
(CA)-AKT/MYC hASCs-CM promoted wound healing
in vivo.
Here we demonstrated, for the first time, that hASCs
immortalization with either hTERT + SV40 or hTERT +
E6/E7 did not substantially affect their potent angiogenic
capabilities. Indeed, although hASCs-TS showed a decrease
in HGF and VEGF secretion compared to hASCs-M CM,
the total amount of secreted factors remained elevated.
More interesting, hASCs-TE showed an increased produc-
tion of HGF and a similar VEGF secretion compared to
hASCs-M CM.
Both hASC-TS and hASC-TE cell lines retained HGF
and VEGF production over time. Further in vivo studies
will need to clarify whether the different secretion level
obtained from hASC-TS and hASC-TE CM may differ-
ently affect their angiogenic potential. Overall, these data
suggest that hASCs-TS and hASCs-TE CM may be useful
for therapeutic strategies.
An important aspect to consider when proto-oncogenes
and lentiviral particles are used to immortalize cells is
CM safety. In-depth in vitro and in vivo studies will be
mandatory to evaluate the absence of potentially danger-
ous agents. Although onco-proteins, unlike oncogenes,
cannot be replicated or amplified, thus reducing the risk
of tumorigenesis, a comprehensive analysis (that is, prote-
omic studies) of CM will be needed to exclude the pres-
ence of altered proteins or factors. A recent study by
Chen et al. [50] demonstrated that MYC-mediated
hESC-MSCs immortalization was effective in producing
an infinite supply of cells for the production of exo-
somes in the milligram range as either therapeutic
agents or delivery vehicles. Interestingly, MYC protein
was present in the transformed cells but was not detect-
able in either the CM or exosomes.
Concerning the lentiviral particles employment, it has to
be considered that here we propose the administration of
CM for therapeutic purposes and this may mitigate the
risk from the integration of lentiviruses. Additionally, the
Figure 8 Evaluation of chromosomal modifications and in vitro transformation. A: Representative karyotype analysis of hASC-M, hASC-T,
hASC-TS and hASC-TE cells at culture passage 26 evidencing alterations in all transduced-cells. B: Soft agar assay of hASCs. Only positive control
gave rise to colony formation. Positive control: PC-3 cell line (tumor prostate); negative control: medium. Magnification 10X.
Figure 9 Fluorescence microscopy images of hASC-TS and hASC-TE fluorescent cells. hASC-TS and hASC-TE cells were transduced with
GFP-lentiviral vectors. Magnification 10X. GFP, green fluorescent protein.
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improved safety and efficacy, will further contribute to
reduce risks [51,52].
Finally, in this study we showed that hASC-TS and
hASC-TE can be stably transduced with GFP, allowing
us to obtain fluorescent cells that maintained their pro-
liferative activity. Preliminary results from our group
indicate the possibility of obtaining clones of fluorescent-
immortalized cells (data not shown); this may represent
an important technical achievement that could lead to the
use of GFP-immortalized cells for in vivo cell-tracking
studies [53,54].
Conclusion
Our study demonstrated that immortalized cell lines
substantially maintained most of the original mesen-
chymal features and, in particular, the capability to pro-
duce significant amounts of angiogenic factors. Further
investigations are needed to find other factors pro-
duced from these cells. However, by combining hASCs
immortalization and their paracrine characteristics, we
developed a “hybridoma-like model” that may have a
potential application for discovering and producing
molecules to use in regenerative medicine (scale-up
process).
In fact, these cells’ growth rate and expansion together
with their secretory capabilities over time could represent
a new strategy for producing large amounts of soluble
factors. Moreover, it is conceivable that conditioned
media could be produced and used instead of the stem
cells, thus reducing the potential risks connected to cell
transplantation, particularly when heterologous cells are
used. In addition, fluorescent-immortalized cells could be
employed in in vivo cell-tracking experiments expanding
their potential use in laboratory practice.
Abbreviations
CM: Conditioned media; DT: Doubling time; FC: Flow cytometry;
FITC: Fluoresceine isothiocyanate; GFP: Green fluorescent protein;
hASCs: Human adipose-derived stromal cells; HGF: Hepatocyte growth factor;
HPV-16: Human papilloma virus 16; hTERT: Human telomerase reverse
transcriptase; MSCs: Mesenchymal stromal cells; PBS: Phosphate-buffered
saline; PDL: Population doubling levels; PE: Phycoerythrin; SSEA-4: Stage
specific embryonic antigen-4; VEGF: Vascular endothelial growth factor.
Competing interests
The purpose of the present paper is to advance the field in an impartial
manner. However, to ensure transparency, the authors acknowledge the
following relationship: LB, AB, MS and AS are employees of Medestea
Research and Production company. Although currently there are neither
pending patents nor commercial developments worldwide, the company
has long been involved in research projects aimed at the use of stem cells
and their derivatives.
Authors’ contributions
LB contributed to manuscript writing, mesenchymal stem cell isolation,
expansion and immortalization, and GFP-transduction. AB contributed to
phenotypic characterization, ELISA assays and data collection. MS was
involved in mesenchymal stem cell isolation, expansion, immortalization and
in vitro transformation and data collection. AS contributed to conceptionand design, and manuscript drafting and revision. AP took part in manuscript
revision, and data analysis and interpretation. ABO and VC contributed to
data collection and analysis. MD was involved in karyotype data collection
and analysis. VT and VC contributed to differentiation experiments, and data
collection and analysis. MLF was involved in GFP-lentiviral particles isolation
and cell-transduction. EAP contributed to the study design and manuscript
revision. GA was involved in the conception and design of the study,
manuscript writing, and data analysis and interpretation. All authors read and
approved the final manuscript.Acknowledgements
We are grateful to Dr. Gaetano Logrieco (Department of Surgery, Hospital
“F. Miulli”, Acquaviva delle Fonti, Bari, Italy) for providing us with human fat
specimens.
We would like to thank Prof. Salvatore Desantis and Dr. Gianluca Accogli
(Department of Emergency and Organ Transplantation, DETO, University of
Bari “Aldo Moro”, Italy) for their valuable suggestions and revisions during
manuscript preparation.
We gratefully acknowledge Dr. Sharon Cox (Department of Emergency and
Organ Transplantation, DETO, University of Bari “Aldo Moro”, Italy) for
providing her English language expertise.
This work was partially co-financed by the Italian Ministry of Education,
University and Research and the European Union within the 2007–2013
National Operational Program for Research and Competitiveness (Project
code: PON01_00829).
Author details
1Medestea Research and Production Laboratories, Consorzio CARSO,
Bari, Italy. 2Department of Biomedical, Surgical and Dental Sciences,
University of Milan, Milan, Italy. 3Department of Cerebrovascular Diseases,
Fondazione IRCCS Neurological Institute Carlo Besta, Milan, Italy. 4Laboratory
of Experimental Neurosurgery and Cell Therapy, Neurosurgery Unit,
Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico, Milan, Italy.
5Institute of Cell Biology and Neurobiology, CNR, Rome, Italy.
Received: 22 November 2013 Revised: 28 January 2014
Accepted: 24 April 2014 Published: 6 May 2014References
1. Mizuno H, Tobita M, Uysal AC: Concise review: adipose-derived stem cells
as a novel tool for future regenerative medicine. Stem Cells 2012,
30:804–810.
2. Gimble JM, Katz AJ, Bunnell BA: Adipose-derived stem cells for
regenerative medicine. Circ Res 2007, 100:1249–1260.
3. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K: Comparative analysis of
mesenchymal stem cells from bone marrow, umbilical cord blood, or
adipose tissue. Stem Cells 2006, 24:1294–1301.
4. Siddappa R, Licht R, van Blitterswijk C, de Boer J: Donor variation and loss
of multipotency during in vitro expansion of human mesenchymal stem
cells for bone tissue engineering. J Orthop Res 2007, 25:1029–1041.
5. Schipper BM, Marra KG, Zhang W, Donnenberg AD, Rubin JP: Regional
anatomic and and age effects on cell function of human adipose-derived
stem cells. Ann Plast Surg 2008, 60:538–544.
6. Binato R, de Souza FT, Lazzarotto-Silva C, Du Rocher B, Mencalha A, Pizzatti
L, Bouzas LF, Abdelhay E: Stability of human mesenchymal stem cells
during in vitro culture: considerations for cell therapy. Cell Prolif 2013,
46:10–22.
7. Serrano M, Blasco MA: Putting the stress on senescence. Curr Opin Cell Biol
2001, 13:748–753.
8. Campisi J: Cellular senescence as a tumor-suppressor mechanism.
Trends Cell Biol 2001, 11:S27–S31.
9. Gudjonsson T, Villadsen R, Rǿnnov-Jessen L, Petersen OW: Immortalization
protocols used in cell culture models oh human breast morphogenesis.
Cell Mol Life Sci 2004, 61:2523–2534.
10. Linder S, Marshall H: Immortalization of primary cells by DNA tumor
viruses. Exp Cell Res 1990, 191:1–7.
11. Jha KK, Banga S, Palejwala V, Ozer HL: SV40-mediated immortalization.
Exp Cell Res 1998, 245:1–7.
12. Hung SC, Yang DM, Chang CF, Lin RJ, Wang JS, Low-Tone Ho L, Yang WK:
Immortalization without neoplastic transformation of human
Balducci et al. Stem Cell Research & Therapy 2014, 5:63 Page 14 of 15
http://stemcellres.com/content/5/3/63mesenchymal stem cells by transduction with HPV16 E6/E7 genes.
Int J Cancer 2004, 110:313–319.
13. Hahn WC, Meyerson M: Telomerase activation, cellular immortalization
and cancer. Ann Med 2001, 33:123–129.
14. Salmon P, Oberholzer J, Occhiodoro T, Morel P, Lou J, Trono D: Reversible
immortalization of human primary cells by lentivector-mediated transfer
of specific genes. Mol Ther 2000, 2:404–414.
15. Darimont C, Zbinden I, Avanti O, Leone-Vautravers P, Giusti V, Burckhardt P,
Pfeifer AMA, Macé K: Reconstitution of telomerase activity combined with
HPV-E7 expression allow human preadipocytes to preserve their
differentiation capacity after immortalization. Cell Death Differ 2003,
10:1025–1031.
16. Zuk PA, Zhu M, Ashjan P, De Ugarte DA, Haung JI, Mizuno H, Alfonso ZC,
Fraser JK, Benhaim P, Hendrick MH: Human adipose tissue is a source of
multipotent stem cells. Mol Biol Cell 2002, 13:4979–4995.
17. Böcker W, Yin Z, Drosse I, Haasters F, Rossmann O, Wierer M, Popov C,
Locher M, Mutschier W, Docheva D, Schieker M: Introducing a single-cell-
derived human mesenchymal stem cell line expressing hTERT after
lentiviral gene transfer. J Cell Mol Med 2008, 12:1347–1359.
18. Zuk PA: Viral transduction of adipose-derived stem cells. Methods Mol Biol
2011, 702:345–357.
19. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L: A
third-generation lentivirus vector with a conditional packaging system.
J Virol 1998, 72:8463–8471.
20. Itahana K, Campisi J, Dimri GP: Methods to detect biomarkers of cellular
senescence: the senescence-associated beta-galactosidase activity.
Methods Mol Biol 2007, 371:21–31.
21. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS,
Deans RJ, Keating A, Prockop DJ, Horwitz EM: Minimal criteria for defining
multipotent mesenchymal stromal cells. The International Society for
Cellular Therapy position statement. Cytotherapy 2006, 8:315–317.
22. De Ugarte DA, Alfonso Z, Zuk PA, Elbarbary A, Zhu M, Ashjian P, Benhaim P,
Hedrick MH, Fraser JK: Differential expression of stem cell mobilization-
associated molecules on multi-lineage cells from adipose tissue and
bone marrow. Immunol Lett 2003, 89:267–270.
23. Sorrentino A, Ferracin M, Castelli G, Biffoni M, Tomaselli G, Baiocchi M, Fatica
A, Negrini M, Peschle C, Valtieri M: Isolation and characterization of CD146+
multipotent mesenchymal stromal cells. Exp Hematol 2008,
36:1035–1046.
24. Gang EJ, Bosnakovski D, Figueiredo CA, Visser JW, Perlingeiro RCR: SSEA-4
identifies mesenchymal stem cells from bone marrow. Blood 2007,
109:1743–1751.
25. Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenkerk JE,
Pell CL, Johnstone BH, Considine RV, March KL: Secretion of angiogenic
and antiapoptotic factors by human adipose stromal cells. Circulation
2004, 109:1292–1298.
26. Li B, Zeng Q, Ang H, Mao X: Effect of cytokines secreted by human
adipose stromal cells on endothelial cells. J Huazhong Univ Sci Technol
Med Sci 2006, 26:396–398.
27. Kilroy GE, Foster SJ, Wu X, Ruiz J, Sherwood S, Heifetz A, Ludlow JW, Stricker
DM, Potiny S, Green P, Halvorsen YD, Cheatham B, Storms RW, Gimble JM:
Cytokine profile of human adipose-derived stem cells: expression of
angiogenic, hematopoietic, and pro-inflammatory factors. J Cell Physiol
2007, 212:702–709.
28. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L,
Gaudino G, Tamagnone L, Coffer A, Comoglio PM: Hepatocyte growth
factor is a potent angiogenic factor which stimulates endothelial cell
motility and growth. J Cell Biol 1992, 119:629–641.
29. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular
endothelial growth factor is a secreted angiogenic mitogen. Science
1989, 246:1306–1309.
30. Polzer H, Volkmer E, Saller MM, Prall WC, Haasters F, Drosse I, Anz D,
Mutschler W, Schieker M: Long-term detection of fluorescently labeled
human mesenchymal stem cell in vitro and in vivo by semi-automated
microscopy. Tissue Eng Part C Methods 2012, 18:156–165.
31. Sen A, Lea-Currie YR, Sujkowska D, Franklin DM, Wilkison WO, Halvorsen YD,
Gimble JM: Adipogenic potential of human adipose derived stromal cells
from multiple donors is heterogeneous. J Cell Biochem 2001, 81:312–319.
32. Griesche N, Luttmann A, Stammermann T, Geiger H, Baer PC: A simple
modification of the separation method reduces heterogeneity of
adipose-derived stem cells. Cells Tissues Organs 2010, 192:106–115.33. Gruber HE, Somayaji S, Riley F, Hoelscher GL, Norton HJ, Ingram J, Hanley
EN Jr: Human adipose-derived mesenchymal stem cells: serial
passaging, doubling time and cell senescence. Biotech Histochem 2012,
87:303–311.
34. Bourin P, Bunnell BA, Casteilla L, Dominici M, Katz AJ, March KL, Redl H, Rubin
JP, Yoshimura K, Gimble JF: Stromal cells from the adipose tissue-derived
stromal cells vascular fraction and culture expanded adipose tissue-derived
stromal/stem cells: a joint statement of the International Federation for
Adipose Therapeutics and Science (IFATS) and the International Society for
Cellular Therapy (ISCT). Cytotherapy 2013, 15:641–648.
35. Voglauer R, Grillari J, Fortschegger K, Wieser M, Sterovsky T, Gunsberg P,
Katinger H, Pfragner R: Establishment of human fibroma cell lines from
MEN1 patient by introduction of either hTERT or SV40 early region.
Int J Oncol 2005, 26:961–970.
36. Tsuruga Y, Kiyono T, Matsushita M, Takahashi T, Kasai H, Matsumoto S, Todo
S: Establishment of immortalized human hepatocytes by introduction of
HPV16 E6/E7 and hTERT as cell sources for liver cell-based therapy.
Cell Transplant 2008, 17:1083–1094.
37. Salgado AJ, Reis RL, Sousa NJ, Gimble JM: Adipose tissue derived stem
cells secretome: soluble factors and their roles in regenerative medicine.
Curr Stem Cell Res Ther 2010, 5:103–110.
38. Jun ES, Lee TH, Cho HH, Suh SY, Jung JS: Expression of telomerase
extends longevity and enhances differentiation in human adipose
tissue-derived stromal cells. Cell Physiol Biochem 2004, 14:261–268.
39. Kang SK, Putnam L, Dufour J, Ylostalo J, Jung JS, Bunnell BA: Expression of
telomerase extends the lifespan and enhances osteogenic differentiation
of adipose tissue-derived stromal cells. Stem Cells 2004, 22:1356–1372.
40. Wolbank S, Stadler G, Peterbauer A, Gillich A, Karbiener M, Streubel B, Wieser M,
Katinger H, van Griensven M, Redl H, Gabriel C, Grillari J, Grillari-Voglauer R:
Telomerase immortalized human amnion- and adipose-derived
mesenchymal stem cells: maintenance of differentiation and
immunomodulatory characteristics. Tissue Eng Part A 2009, 15:1843–1854.
41. Chapman S, Liu X, Meyers C, Schlegel R, McBride AA: Human keratinocytes
are efficiently immortalized by a Rho kinase inhibitor. J Clin Invest 2010,
120:2619–2626.
42. Duncan EL, Wadhwa R, Kaul SC: Senescence and immortalization of
human cells. Biogerontology 2000, 1:103–121.
43. Tátrai P, Szepesi Á, Matula Z, Szigeti A, Buchan G, Mádi A, Uher F, Német K:
Combined introduction of Bmi-1 and hTERT immortalizes human
adipose tissue-derived stromal cells with low risk of transformation.
Biochem Biophys Res Commun 2012, 422:28–35.
44. Gnecchi M, Zhang Z, Ni A, Dzau VJ: Paracrine mechanisms in adult stem
cells signaling and therapy. Circ Res 2008, 103:1204–1219.
45. De Siena R, Balducci L, Blasi A, Montanaro MG, Saldarelli M, Saponaro V,
Martino C, Logrieco G, Soleti A, Fiobellot S, Madeddu P, Rossi G, Ribatti D,
Crovace A, Cristini S, Invernici G, Parati EA, Alessandri G: Omentum-derived
stromal cells improve myocardial regeneration in pig post-infarcted
heart through a potent paracrine mechanism. Exp Cell Res 2010,
316:1804–1815.
46. Madonna R, Taylor DA, Geng YJ, De Caterina R, Shelat H, Perin EC, Willerson JT:
Transplantation of mesenchymal cells rejuvenated by the overexpression
of telomerase and myocardin promotes revascularization and tissue
repair in a murine model of hindlimb ischemia. Circ Res 2013,
113:902–914.
47. Watson SL, Marcal H, Sarris M, Di Girolamo N, Coroneo MT, Wakefield D: The
effect of mesenchymal stem cell conditioned media on corneal stromal
fibroblast wound healing activities. Br J Ophthalmol 2010, 94:1067–1073.
48. Cho YJ, Song HS, Bhang S, Lee S, Kang BG, Lee JC, An J, Cha CI, Nam DH,
Kim BS, Joo KM: Therapeutic effects of human adipose stem cell-
conditioned medium on stroke. J Neurosci Res 2012, 90:1794–1802.
49. Song SH, Lee MO, Lee JS, Jeong HC, Kim HG, Kim WS, Hur M, Cha HJ: Genetic
modification of human adipose-derived stem cells for promoting wound
healing. J Dermatol Sci 2012, 66:98–107.
50. Chen TS, Arslan F, Yin Y, Tan SS, Lai RC, Choo AB, Padmanabhan J, Lee CN,
de Klein DP, Lim S: Enabling a robust scalable manufacturing process for
therapeutic exosomes through oncogenic immortalization of human
ESC-derived MSCs. J Transl Med 2011, 9:47.
51. Mátrai J, Chuah MK, VandenDriessche T: Recent advances in lentiviral
vector development and applications. Mol Ther 2010, 18:1055.
52. Picanco-Castro V, de Sousa Russo-Carbolante EM, Tadeu CD: Advances in
lentiviral vectors: a patent review. Recent Pat DNA Gene Seq 2012, 6:82–90.
Balducci et al. Stem Cell Research & Therapy 2014, 5:63 Page 15 of 15
http://stemcellres.com/content/5/3/6353. Vilalta M, Dégano IR, Bagó J, Gould D, Santos M, García-Arranz M, Ayats R,
Fuster C, Chernajovsky Y, García-Olmo D, Rubio N, Blanco J: Biodistribution,
long-term survival, and safety of human adipose tissue-derived
mesenchymal stem cells transplanted in nude mice by high sensitivity
non-invasive bioluminescence imaging. Stem Cells Dev 2008, 17:993–1003.
54. Progatzky F, Dallman MJ, Lo Celso C: From seeing to believing: labelling
strategies for in vivo cell-tracking experiments. Interface Focus 2013,
3:20130001.
doi:10.1186/scrt452
Cite this article as: Balducci et al.: Immortalization of human
adipose-derived stromal cells: production of cell lines with high growth
rate, mesenchymal marker expression and capability to secrete high
levels of angiogenic factors. Stem Cell Research & Therapy 2014 5:63.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
